KRAS and neoplasm: We chose a novel ERK1/2-selective pharmacologic inhibitor, SCH772984, which has shown cellular potency in tumor cells with BRAF, NRAS, or KRAS mutations and induces tumor regressions in xenograft models at toxicity-free doses [32].